Synapse - Works

Results (5712)

Quality of life, functioning, and symptoms in patients with previously treated locally advanced or metastatic urothelial carcinoma from EV-301

Meeting Abstract

Gurney, H.; Mamtani, R.; Rosenberg, J. E.; Powles, T.; Sonpavde, G. P.; Loriot, Y.; Duran, I.; Lee, J. L.; Matsubara, N.; Vulsteke, C.; more...
Swiss Medical Weekly (2021)

Fulltext@MSK | Save

Selpercatinib efficacy and safety in patients with RET-altered thyroid cancer: A clinical trial update

Meeting Abstract

Sherman, E.; Wirth, L.; Shah, M.; Cabanillas, M.; Robinson, B.; Italiano, A.; Laskin, J.; Subbiah, V.; Drilon, A.; Wright, J.; more...
Swiss Medical Weekly (2021)

Fulltext@MSK | Save

Post hoc analysis of the CLEAR study in advanced renal cell carcinoma (RCC): Effect of subsequent therapy on survival outcomes in the lenvatinib (L) plus everolimus (E) vs sunitinib (S) treatment arms

Meeting Abstract

Grünwald, V.; Hutson, T.; Choueiri, T. K.; Motzer, R.; Rha, S. Y.; Alyasova, A.; Merchan, J.; Gurney, H.; Peer, A.; Takagi, T.; more...
Oncology Research and Treatment (2021)

Fulltext@MSK | Save

Resistance to type II JAK2 inhibition in MPN is dependent on chromatin remodeling and MAPK activation and is targetable

Meeting Abstract

Szybinski, J.; Codilupi, T.; Stivala, S.; Brkic, S.; Yang, J. L.; Wicki, A.; Ghosh, N.; Passweg, J.; Dirnhofer, S.; Levine, R. L.; more...
Swiss Medical Weekly (2021)

Fulltext@MSK | Save

MERMAID-2: Phase 3 study of durvalumab in patients with resected, stage II-III NSCLC who become MRD plus after curative-intent therapy

Meeting Abstract

Reinmuth, N.; Spigel, D.; Peters, S.; Ahn, M. J.; Tsuboi, M.; Chaft, J.; Harpole, D.; Barlesi, F.; Abbosh, C.; Mann, H.; more...
Oncology Research and Treatment (2021)

Fulltext@MSK | Save

Health-related quality of life (HRQoL) with adjuvant nivolumab (NIVO) vs placebo (PBO) after radical resection for high-risk muscle-invasive urothelial carcinoma (MIUC): Results from the phase 3 CheckMate 274 trialep138

Meeting Abstract

Gschwend, J. E.; Bajorin, D.; Galsky, M.; Broughton, E.; Braverman, J.; Koon, H.; Maira-Arce, M.; Hamilton, M.; Shi, L.; Guo, S.; more...
Oncology Research and Treatment (2021)

Fulltext@MSK | Save

The CAR-HEMATOTOX model identifies patients with a high risk for CAR T-cell related hematotoxicity and is associated with prolonged hospitalization and poor prognosis

Meeting Abstract

Rejeski, K.; Perez, A.; Sesques, P.; Berger, C.; Jentzsch, L.; Mougiakakos, D.; Frölich, L.; Ackermann, J.; Bücklein, V.; Blumenberg, V.; more...
Oncology Research and Treatment (2021)

Fulltext@MSK | Save

Polo: Subsequent therapy after maintenance olaparib in patients with a germline BRCA mutation and metastatic pancreatic cancer

Meeting Abstract

Arnold, D.; Golan, T.; Hammel, P.; Reni, M.; Van Cutsem, E.; Macarulla, T.; Hall, M. J.; Park, J. O.; Hochhauser, D.; Oh, D. Y.; more...
Oncology Research and Treatment (2021)

Fulltext@MSK | Save

Matterhorn: Efficacy and safety of neoadjuvant-adjuvant durvalumab and FLOT chemotherapy in resectable gastric and gastroesophageal junction cancer - A randomized, doubleblind, placebo-controlled, phase 3 study

Meeting Abstract

Al-Batran, S. E.; Janjigian, Y.; Van Cutsem, E.; Muro, K.; Wainberg, Z.; Hyung, W. J.; Molena, D.; Evans, B.; Ruscica, D.; Robbins, S. H.; more...
Oncology Research and Treatment (2021)

Fulltext@MSK | Save

Outcomes in patients (pts) aged ≥ 65 years in the phase 3 ASCENT study of sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC)

Meeting Abstract

Hegewisch-Becker, S.; Oliveira, M.; Traina, T.; Tolaney, S. M.; Loirat, D.; Punie, K.; Hurvitz, S. A.; Lynce, F.; Hamilton, E.; Nanda, R.; more...
Oncology Research and Treatment (2021)

Fulltext@MSK | Save